Noom Makes Its GLP-1 Companion Free, Betting on the Weight-Regain Problem
With payers scrutinizing what happens after patients stop GLP-1s, Noom is giving away structured behavioral support — claiming members regain less than 2% of body weight in the year after stopping medication.
Noom has launched a free tier of its GLP-1 Companion program, giving anyone on GLP-1 medications no-cost structured behavioral support — and positioning the product as a tool providers can hand to patients to prevent the weight regain that follows medication discontinuation.
The free tier includes medication and side-effect tracking, personalized protein targets, AI meal logging, Muscle Defense workouts through a FitOn partnership, body-composition scans, and a rewards system. CEO Geoff Cook and Chief Medical Officer Dr. Jeffrey Egler framed the launch around durability: weight loss that lasts after the prescription ends.
The regain problem is the market
Noom's company-reported numbers make the strategic logic explicit: users on GLP-1s lose 1.4x more weight than medication alone; in its largest randomized controlled trial, members lost an average 4.1% body weight and kept losing for a full year after program completion; and high-habit users regained about 50% less weight per month. (These are company trial claims, not independently verified.)
The launch intensifies competition among GLP-1 wraparound platforms — Omada, Hims & Hers, WeightWatchers — as payers scrutinize discontinuation and regain rates. Notably, Noom says it has updated the Companion in anticipation of FDA's Prescription Drug Use-Related Software (PDURS) framework, which could make drugmaker-linked companion apps label-referenced — a regulatory hook that would turn behavioral wrappers from marketing into medicine.
Reporting: Noom press release via GlobeNewswire, June 24, 2026.
Source
Original reporting: GlobeNewswire / Noom ↗